Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Down 83.0% in July

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 8,448 shares, a decline of 83.0% from the July 15th total of 49,784 shares. Based on an average trading volume of 31,236 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned about 0.66% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors.

Sonoma Pharmaceuticals Price Performance

NASDAQ SNOA traded down $0.03 during trading on Wednesday, reaching $1.34. 38,784 shares of the company’s stock traded hands, compared to its average volume of 137,247. The firm has a market cap of $6.40 million, a price-to-earnings ratio of -1.10 and a beta of 1.28. The company’s 50 day simple moving average is $1.18 and its two-hundred day simple moving average is $1.85. Sonoma Pharmaceuticals has a 12-month low of $0.85 and a 12-month high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.32. Sonoma Pharmaceuticals had a negative return on equity of 26.32% and a negative net margin of 10.33%.The business had revenue of $6.41 million for the quarter, compared to the consensus estimate of $4.99 million.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Sonoma Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.